MCID: INS024
MIFTS: 83

Insulin-Like Growth Factor I

Categories: Genetic diseases, Rare diseases, Mental diseases, Ear diseases, Neuronal diseases, Endocrine diseases

Aliases & Classifications for Insulin-Like Growth Factor I

MalaCards integrated aliases for Insulin-Like Growth Factor I:

Name: Insulin-Like Growth Factor I 53
Insulin-Like Growth Factor I Deficiency 53 49 71 36 28 69
Igf1 Deficiency 53 49 71 51
Insulin-Like Growth Factor I, Resistance to 53 13 69
Growth Retardation with Deafness and Mental Retardation Due to Igf1 Deficiency 53 13
Growth Retardation with Sensorineural Deafness and Mental Retardation 53 49
Growth Delay Due to Insulin-Like Growth Factor I Resistance 55 36
Insulin-Like Growth Factor 1 Resistance to 49 28
Igf-I Resistance 53 51
Igf1res 53 71
Growth Delay Due to Insulin-Like Growth Factor Type 1 Deficiency 55
Growth Delay-Deafness- Intellectual Disability Syndrome 55
Primary Insulin-Like Growth Factor Deficiency 55
Resistance to Insulin-Like Growth Factor I 71
Somatomedin, End-Organ Insensitivity to 53
Insulin-Like Growth Factor 1 Resistance 71
Somatomedin End-Organ Insensitivity to 49
End-Organ Insensitivity to Somatomedin 71
Somatomedin-C, Resistance to 53
Somatomedin-C Resistance to 49
Resistance to Somatomedin-C 71
Resistance to Igf-1 55
Igf-1 Resistance 49
Igf-1 Deficiency 55
Igf1 Resistance 71
Somatomedin-C 53

Characteristics:

Orphanet epidemiological data:

55
growth delay due to insulin-like growth factor type 1 deficiency
Inheritance: Autosomal recessive; Prevalence: <1/1000000 (Worldwide); Age of onset: Infancy,Neonatal;
growth delay due to insulin-like growth factor i resistance
Inheritance: Autosomal dominant,Autosomal recessive; Age of onset: Infancy,Neonatal;

OMIM:

53
Inheritance:
autosomal recessive
autosomal dominant

Miscellaneous:
onset in utero
dominant and recessive patients have iugr, short stature, and microcephaly
heterozygous relatives of some biallelic patients appear to be unaffected


HPO:

31
insulin-like growth factor i:
Onset and clinical course congenital onset
Inheritance autosomal recessive inheritance autosomal dominant inheritance

insulin-like growth factor i deficiency:
Onset and clinical course congenital onset
Inheritance autosomal recessive inheritance


Classifications:

Orphanet: 55  
Rare endocrine diseases


Summaries for Insulin-Like Growth Factor I

NIH Rare Diseases : 49 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs.Orpha Number: 73273Disease definitionGrowth delay due to IGF-I resistance is characterised by variable intrauterine and postnatal growth retardation and elevated serum IGF-I levels. Addition features include variable degrees of intellectual deficit, microcephaly and dysmorphism (broad nasal bridge and tip, smooth philtrum, thin upper and everted lower lips, short fingers, clinodactyly, wide-set nipples and pectus excavatum).EpidemiologyPrevalence is unknown.EtiologyIGF-I resistance may be caused by a variety of genetic defects: ring chromosome 15, distal heterozygous 15q deletions encompassing the IGF1R gene (15q26.3), or IGF1R gene mutations. Intellectual deficit is pronounced in patients with ring chromosome 15 but varies depending on the size of the deletion and on the functions of other deleted genes in patients with 15q deletions. Partial IGF-I insensitivity due to IGF1R haploinsufficiency has been reported in one patient with a small deletion encompassing one allele of the IGF1R gene and was characterised by small size for gestational age, persistent growth failure that improved considerably with GH therapy, and the absence of intellectual deficit. IGF1R mutations have been described in six patients so far and were associated with variable growth delay and degrees of intellectual deficit.Diagnostic methodsDiagnosis relies on karyotyping for detection of ring chromosome 15, detection of small deletions encompassing IGF1R and detection of IGF1R mutations by sequence variation screening methods or by direct sequencing of the 21 IGF1R exons and their intron-exon junctions.Differential diagnosisThe differential diagnosis should include bio-inactive IGF-I resulting in IGF-I deficiency (see this term). Measurement of IGF-I levels can be used for diagnosis but circulating levels of IGF-I may vary over time for the same patient and may not be elevated in case of poor nutritional status.Antenatal diagnosisPrenatal diagnosis has not been reported and is complicated by the variable expressivity (even within the same family) of some of the reported mutations, especially in terms of their impact on intellectual development.Genetic counselingIn all but one of these patients, the mutations were heterozygous and transmitted as an autosomal dominanttrait. Affected families should be offered genetic counselling and informed of a 50% risk of recurrence for dominant inheritance and of a 25% risk of recurrence for recessive transmission.Management and treatmentManagement involves nutritional and developmental support. Although deafness has not yet been reported in patients with IGF-I resistance, it is present in some patients with IGF-I deficiency (caused by mutations in the gene encoding the IGF1R ligand, IGFI). As a result, screening for deafness should be proposed for all patients with IGF-I resistance. Some patients with IGF-I resistance show increased growth velocity with recombinant GH therapy while others show no response.PrognosisPrognosis varies depending on the underlying molecular anomaly.Visit the Orphanet disease page for more resources. Last updated: 5/22/2008

MalaCards based summary : Insulin-Like Growth Factor I, also known as insulin-like growth factor i deficiency, is related to laron syndrome and acid-labile subunit deficiency, and has symptoms including pectus excavatum, clinodactyly and ptosis. An important gene associated with Insulin-Like Growth Factor I is IGF1 (Insulin Like Growth Factor 1), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Oocyte meiosis. The drugs Clonidine and Estradiol have been mentioned in the context of this disorder. Affiliated tissues include breast, bone and prostate, and related phenotypes are Decreased viability and Decreased viability

OMIM : 53 Patients with mutations in the receptor for insulin-like growth factor I show intrauterine growth retardation and postnatal growth failure, resulting in short stature and microcephaly. Other features may include delayed bone age, developmental delay, and dysmorphic features. (270450)

UniProtKB/Swiss-Prot : 71 Insulin-like growth factor 1 resistance: A disorder characterized by intrauterine growth retardation, poor postnatal growth and increased plasma IGF1 levels. Insulin-like growth factor I deficiency: Autosomal recessive disorder characterized by growth retardation, sensorineural deafness and mental retardation.

Related Diseases for Insulin-Like Growth Factor I

Diseases related to Insulin-Like Growth Factor I via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 340)
# Related Disease Score Top Affiliating Genes
1 laron syndrome 33.2 GH1 GHR IGF1 IGF2 IGFBP3
2 acid-labile subunit deficiency 33.1 IGF1 IGF2 IGFBP3
3 growth hormone deficiency 31.7 GH1 IGF1 IGFBP3
4 acromegaly 31.3 GH1 GHR IGF1 IGF2 IGFBP1 IGFBP3
5 polycystic ovary syndrome 31.1 IGF1 IGFBP1 INS INSR IRS1
6 bulimia nervosa 2 31.0 GH1 GHR IGF1
7 hyperandrogenism 30.9 IGF1 IGFBP1 INS INSR
8 hyperglycemia 30.9 IGF1 INS INSR IRS1
9 osteoporosis 30.8 GH1 GHR IGF1 IGFBP3 IGFBP4 IGFBP5
10 isolated growth hormone deficiency 30.7 GH1 GHR IGF1
11 pineal hyperplasia, insulin-resistant diabetes mellitus, and somatic abnormalities 30.7 IGF1 IGFBP3 INS INSR
12 turner syndrome 30.7 GH1 GHR IGF1 IGFBP1 IGFBP3
13 body mass index quantitative trait locus 11 30.7 AKT1 GH1 GHR IGF1 IGFBP1 IGFBP2
14 secondary adrenal insufficiency 30.6 IGF1 IGFBP3 INS
15 ovarian disease 30.6 IGF1 IGFBP1 INS
16 diabetes mellitus 30.5 AKT1 AKT2 IGF1 INS INSR IRS1
17 glucose intolerance 30.5 GH1 IGF1 IGFBP1 INS INSR IRS1
18 hypopituitarism 30.5 GH1 IGF1 IGFBP3 INS
19 silver-russell syndrome 30.5 IGF1 IGF2 IGFBP1 IGFBP3
20 glioblastoma multiforme 30.4 AKT1 EGF IGF1 IGF1R IGFBP2
21 hyperinsulinism 30.4 IGF1 IGFBP1 IGFBP3 INS INSR
22 fetal macrosomia 30.3 IGF1 IGF2 IGFBP3 INS INSR
23 prader-willi syndrome 30.3 GH1 GHR IGF1 IGF2 IGFBP1 IGFBP3
24 medulloblastoma 30.1 AKT1 IGF1R IGF2 IRS1
25 endometrial cancer 29.9 AKT1 AKT2 EGF IGF1 IGF1R IGFBP1
26 glioblastoma 29.8 AKT1 AKT2 EGF IGF1R
27 breast cancer 29.7 AKT1 AKT2 EGF IGF1 IGF1R IGF2
28 prostate cancer 29.5 AKT1 AKT2 EGF IGF1 IGF1R IGF2
29 diabetes mellitus, noninsulin-dependent 28.6 AKT1 AKT2 GH1 IGF1 IGF1R IGF2
30 growth hormone insensitivity with immunodeficiency 11.5
31 growth factors, combined defect of 11.4
32 kowarski syndrome 11.2
33 prostatitis 10.8
34 aging 10.7
35 blood group, i system 10.7
36 mixed cell adenoma 10.6 IGF1 IRS1
37 insulin autoimmune syndrome 10.6 INS INSR
38 slipped capital femoral epiphysis 10.6 IGF1 IGFBP3
39 pituitary adenoma 1, multiple types 10.6 GH1 IGF1 IGFBP3
40 malignant ovarian cyst 10.6 IGF1 IGFBP2
41 body mass index quantitative trait locus 9 10.6
42 body mass index quantitative trait locus 8 10.6
43 body mass index quantitative trait locus 7 10.6
44 body mass index quantitative trait locus 12 10.6
45 body mass index quantitative trait locus 14 10.6
46 body mass index quantitative trait locus 18 10.6
47 body mass index quantitative trait locus 4 10.6
48 body mass index quantitative trait locus 10 10.6
49 fasting hypoglycemia 10.6 IGF1 IGF2 INSR
50 complete androgen insensitivity syndrome 10.6 IGF2 IGFBP2 IGFBP3

Graphical network of the top 20 diseases related to Insulin-Like Growth Factor I:



Diseases related to Insulin-Like Growth Factor I

Symptoms & Phenotypes for Insulin-Like Growth Factor I

Symptoms via clinical synopsis from OMIM:

53
Neurologic Behavioral Psychiatric Manifestations:
agitation
anxious affect
obsessive tendencies

Neurologic Central Nervous System:
global developmental delay
delayed motor development
mental retardation
speech delay
developmental delay, mild
more
Growth Height:
short stature

Head And Neck Face:
triangular face
long, smooth philtrum
facial dysmorphism (in some patients)
receding hairline
progeroid appearance (in some recessive patients)
more
Skeletal:
delayed bone age

Growth Weight:
low weight

Chest External Features:
pectus excavatum (rare)

Head And Neck Eyes:
deep-set eyes (recessive)
strabismus (recessive)
synophrys (recessive)
arched eyebrows (recessive)
upslanting palpebral fissures (recessive)
more
Head And Neck Neck:
pterygium colli (recessive)

Cardiovascular Vascular:
narrowing of pulmonary branch arteries (recessive)
continuation of inferior vena cava to azygos vein (recessive)

Skin Nails Hair Skin:
axillary acanthosis nigricans (recessive)

Muscle Soft Tissue:
reduced subcutaneous fat (recessive)
truncal obesity (recessive)
lipodystrophy (recessive)

Endocrine Features:
elevated baseline insulin (recessive)
diabetes mellitus, type 2 (in some heterozygous adults)
diabetes mellitus, type 1 (in 1 recessive adolescent patient)

Skeletal Hands:
clinodactyly
short fingers
small hands

Head And Neck Head:
microcephaly

Growth Other:
intrauterine growth retardation
poor growth

Head And Neck Nose:
broad nasal bridge

Head And Neck Mouth:
thin upper lip
fleshy lower lip
high-arched palate (recessive)
small mouth (recessive)

Skeletal Feet:
small feet
sandal gap (recessive)

Head And Neck Ears:
low-set ears (recessive)

Head And Neck Teeth:
delayed eruption of dentition (recessive)
small opalescent teeth (recessive)
brittle teeth (recessive)
eroded teeth (recessive)

Cardiovascular Heart:
patent foramen ovale (recessive)
atrial septal defect (recessive)
ventricular septal defect (recessive)

Chest Breasts:
widely spaced nipples (rare)

Skin Nails Hair Hair:
sparse scalp hair (recessive)

Voice:
high-pitched voice (recessive)

Laboratory Abnormalities:
increased serum insulin-like growth factor-1 (igf1, )
increased or normal serum growth hormone (gh, )


Clinical features from OMIM:

270450 608747

Human phenotypes related to Insulin-Like Growth Factor I:

55 31 (show top 50) (show all 62)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 pectus excavatum 55 31 frequent (33%) Frequent (79-30%) HP:0000767
2 clinodactyly 55 31 frequent (33%) Frequent (79-30%),Frequent (79-30%) HP:0030084
3 ptosis 55 31 Occasional (29-5%) HP:0000508
4 intellectual disability 55 31 frequent (33%) Very frequent (99-80%),Frequent (79-30%) HP:0001249
5 failure to thrive 55 31 hallmark (90%) Very frequent (99-80%) HP:0001508
6 delayed skeletal maturation 55 31 frequent (33%) Frequent (79-30%),Very frequent (99-80%) HP:0002750
7 wide nasal bridge 55 31 frequent (33%) Frequent (79-30%) HP:0000431
8 abnormal facial shape 55 31 hallmark (90%) Very frequent (99-80%) HP:0001999
9 microcephaly 55 31 hallmark (90%) Very frequent (99-80%),Frequent (79-30%) HP:0000252
10 smooth philtrum 55 31 frequent (33%) Frequent (79-30%) HP:0000319
11 sensorineural hearing impairment 55 31 Very frequent (99-80%) HP:0000407
12 short stature 55 31 hallmark (90%) Very frequent (99-80%),Very frequent (99-80%) HP:0004322
13 intellectual disability, mild 55 31 hallmark (90%) Very frequent (99-80%) HP:0001256
14 osteoporosis 55 31 frequent (33%) Frequent (79-30%) HP:0000939
15 prominent forehead 55 31 occasional (7.5%) Occasional (29-5%) HP:0011220
16 hypoglycemia 55 31 occasional (7.5%) Occasional (29-5%) HP:0001943
17 micrognathia 55 31 frequent (33%) Frequent (79-30%) HP:0000347
18 delayed eruption of teeth 55 31 frequent (33%) Frequent (79-30%) HP:0000684
19 short palm 55 31 frequent (33%) Frequent (79-30%) HP:0004279
20 concave nasal ridge 55 31 occasional (7.5%) Occasional (29-5%) HP:0011120
21 everted lower lip vermilion 55 31 frequent (33%) Frequent (79-30%) HP:0000232
22 attention deficit hyperactivity disorder 55 31 hallmark (90%) Very frequent (99-80%) HP:0007018
23 intrauterine growth retardation 55 31 hallmark (90%) Very frequent (99-80%),Very frequent (99-80%) HP:0001511
24 wide intermamillary distance 55 31 frequent (33%) Frequent (79-30%) HP:0006610
25 low posterior hairline 55 31 occasional (7.5%) Occasional (29-5%) HP:0002162
26 myopia 55 31 occasional (7.5%) Occasional (29-5%) HP:0000545
27 hypogonadism 55 31 frequent (33%) Frequent (79-30%) HP:0000135
28 clinodactyly of the 5th finger 55 31 frequent (33%) Frequent (79-30%) HP:0004209
29 broad nasal tip 55 31 frequent (33%) Frequent (79-30%) HP:0000455
30 low anterior hairline 55 31 occasional (7.5%) Occasional (29-5%) HP:0000294
31 thin vermilion border 55 31 frequent (33%) Frequent (79-30%) HP:0000233
32 congenital sensorineural hearing impairment 55 31 hallmark (90%) Very frequent (99-80%) HP:0008527
33 motor delay 55 31 occasional (7.5%) Occasional (29-5%),Frequent (79-30%) HP:0001270
34 truncal obesity 55 31 occasional (7.5%) Occasional (29-5%) HP:0001956
35 severe postnatal growth retardation 55 31 hallmark (90%) Very frequent (99-80%) HP:0008850
36 hyperactivity 55 31 Very frequent (99-80%) HP:0000752
37 single transverse palmar crease 55 31 occasional (7.5%) Occasional (29-5%) HP:0000954
38 insulin resistance 55 31 hallmark (90%) Very frequent (99-80%) HP:0000855
39 cafe-au-lait spot 55 31 occasional (7.5%) Occasional (29-5%) HP:0000957
40 severe intrauterine growth retardation 55 31 hallmark (90%) Very frequent (99-80%) HP:0008846
41 small for gestational age 55 31 hallmark (90%) Very frequent (99-80%) HP:0001518
42 small placenta 55 31 frequent (33%) Frequent (79-30%) HP:0006266
43 bilateral sensorineural hearing impairment 55 31 hallmark (90%) Very frequent (99-80%) HP:0008619
44 neonatal hyperbilirubinemia 55 31 frequent (33%) Frequent (79-30%) HP:0003265
45 short attention span 55 31 Very frequent (99-80%) HP:0000736
46 prelingual sensorineural hearing impairment 55 31 hallmark (90%) Very frequent (99-80%) HP:0000399
47 congenital bilateral ptosis 55 31 occasional (7.5%) Occasional (29-5%) HP:0007911
48 agitation 31 HP:0000713
49 osteopenia 31 HP:0000938
50 behavioral abnormality 55 Very frequent (99-80%)

UMLS symptoms related to Insulin-Like Growth Factor I:


agitation

GenomeRNAi Phenotypes related to Insulin-Like Growth Factor I according to GeneCards Suite gene sharing:

25 (show all 24)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.5 ITGB3
2 Decreased viability GR00221-A-1 10.5 AKT2 INSR IGF1R AKT1 IRS1
3 Decreased viability GR00221-A-2 10.5 INSR IGF1R AKT1 ITGAV ITGB3 IRS1
4 Decreased viability GR00221-A-3 10.5 AKT2 INSR IGF1R AKT1
5 Decreased viability GR00221-A-4 10.5 AKT2 INSR AKT1 ITGB3
6 Decreased viability GR00301-A 10.5 AKT2 IGF1R
7 Decreased viability GR00342-S-2 10.5 IGF1R IRS1
8 Decreased viability GR00342-S-3 10.5 AKT2 IRS1
9 Decreased viability GR00381-A-1 10.5 ITGAV
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-139 10.19 GH1
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-142 10.19 INSR
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 10.19 IGF1R
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 10.19 IGF1R
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-155 10.19 GH1
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-18 10.19 INSR
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 10.19 INSR AKT1
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-27 10.19 AKT2
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-40 10.19 INSR
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 10.19 AKT2 GH1 INSR AKT1 IGF1R
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 10.19 INSR
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-87 10.19 IGF1R
22 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.8 IGF1R AKT2 ITGA6 ITGAV ITGB3 IRS1
23 Increased cell death HMECs cells GR00103-A-0 9.5 IGFBP6 INS INSR IGF1R IGFBP4 ITGAV
24 Increased cell viability after pRB stimulation GR00230-A-1 8.92 AKT2 INSR IGF1R AKT1

MGI Mouse Phenotypes related to Insulin-Like Growth Factor I:

43 (show all 20)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.44 ITGAV IRS1 ITGB3 ITGA6 IGF1R IGF1
2 endocrine/exocrine gland MP:0005379 10.42 ITGAV IRS1 ITGA6 IGF1R IGF1 IGF2
3 cardiovascular system MP:0005385 10.4 ITGAV IRS1 ITGB3 ITGA6 IGF2 IGF1R
4 cellular MP:0005384 10.39 ITGB3 ITGA6 ITGAV IRS1 IGF2 IGF1R
5 immune system MP:0005387 10.37 ITGAV IRS1 ITGB3 ITGA6 IGF2 IGF1R
6 homeostasis/metabolism MP:0005376 10.36 ITGB3 ITGAV IRS1 IGF2 IGF1R IGF1
7 hematopoietic system MP:0005397 10.34 ITGB3 ITGA6 ITGAV IRS1 IGF2 IGF1R
8 adipose tissue MP:0005375 10.33 IRS1 IGF1R IGF1 GHR AKT2 AKT1
9 muscle MP:0005369 10.25 ITGAV IRS1 ITGB3 IGF1R IGF2 AKT2
10 integument MP:0010771 10.22 ITGA6 ITGB3 IGF2 IGF1R IGF1 GHR
11 liver/biliary system MP:0005370 10.21 IRS1 ITGB3 IGF1R IGFBP1 IGF2 AKT2
12 digestive/alimentary MP:0005381 10.17 ITGA6 ITGB3 INSR ITGAV IGF2 IGF1R
13 embryo MP:0005380 10.16 ITGA6 ITGAV ITGB3 IGF2 IGF1R AKT1
14 nervous system MP:0003631 10.06 ITGA6 INSR ITGAV ITGB3 IGF1 IGF2
15 limbs/digits/tail MP:0005371 10 ITGA6 IRS1 IGF1 IGF2 IGF1R GHR
16 renal/urinary system MP:0005367 9.96 ITGAV ITGB3 ITGA6 IGF2 IGF1 GHR
17 neoplasm MP:0002006 9.91 ITGA6 ITGAV ITGB3 IGF1 IGF1R AKT1
18 reproductive system MP:0005389 9.85 ITGB3 INSR IGF1 IGF2 IGF1R GHR
19 respiratory system MP:0005388 9.61 ITGB3 ITGA6 IGF2 IGF1R IGF1 AKT2
20 skeleton MP:0005390 9.32 ITGB3 IRS1 IGF1 IGF2 IGF1R AKT1

Drugs & Therapeutics for Insulin-Like Growth Factor I

Drugs for Insulin-Like Growth Factor I (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 503)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clonidine Approved Phase 4,Phase 2,Phase 3 4205-90-7 2803
2
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 50-28-2 5757
3
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 83150-76-9 6400441 383414
4
Zinc Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 7440-66-6 32051 23994
5
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1 657-24-9 4091 14219
6
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
7
Tibolone Approved, Investigational Phase 4 5630-53-5
8 lanreotide Approved Phase 4,Phase 3,Phase 2,Phase 1 108736-35-2
9
Somatostatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 38916-34-6, 51110-01-1 53481605
10
Cabergoline Approved Phase 4,Phase 3 81409-90-7 54746
11
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
12
Fosinopril Approved Phase 4 98048-97-6 55891
13
Sodium oxybate Approved Phase 4 502-85-2 5360545
14
Insulin Aspart Approved Phase 4 116094-23-6 16132418
15
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
16
Topiramate Approved Phase 4 97240-79-4 5284627
17
Valproic Acid Approved, Investigational Phase 4 99-66-1 3121
18
Anastrozole Approved, Investigational Phase 4,Phase 2 120511-73-1 2187
19
Ethinyl Estradiol Approved Phase 4,Phase 2,Phase 3 57-63-6 5991
20
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 3 51-43-4 5816
21 Racepinephrine Approved Phase 4,Phase 2,Phase 3 329-65-7
22
Insulin Detemir Approved Phase 4,Phase 3 169148-63-4 5311023
23
Citalopram Approved Phase 4 59729-33-8 2771
24
Vortioxetine Approved, Investigational Phase 4 508233-74-7 9966051
25
Letrozole Approved, Investigational Phase 4,Phase 2 112809-51-5 3902
26
Liraglutide Approved Phase 4,Phase 2 204656-20-2 44147092
27
Desogestrel Approved Phase 4 54024-22-5 40973
28
Etonogestrel Approved, Investigational Phase 4 54048-10-1 6917715 40976
29
Norelgestromin Approved, Investigational Phase 4 53016-31-2 13752005
30
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
31
Verapamil Approved Phase 4 52-53-9 2520
32
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
33
gamma-Aminobutyric acid Approved, Investigational Phase 4 56-12-2 119
34
Dehydroepiandrosterone Approved, Investigational, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1 53-43-0 9860744
35 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
36 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
37 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
38 Imatinib Mesylate Phase 4 123596
39 Adrenergic Agents Phase 4,Phase 2,Phase 3
40 Adrenergic Agonists Phase 4,Phase 2,Phase 3
41 Adrenergic alpha-2 Receptor Agonists Phase 4,Phase 2,Phase 3
42 Adrenergic alpha-Agonists Phase 4,Phase 2,Phase 3
43 Analgesics Phase 4,Phase 2,Phase 3,Phase 1
44 Antihypertensive Agents Phase 4,Phase 2,Phase 3,Phase 1
45 Autonomic Agents Phase 4,Phase 2,Phase 3,Phase 1
46 Contraceptive Agents Phase 4,Phase 2,Phase 3,Phase 1
47 Estradiol 17 beta-cypionate Phase 4,Phase 2,Phase 3,Phase 1
48 Estradiol 3-benzoate Phase 4,Phase 2,Phase 3,Phase 1
49 Estradiol valerate Phase 4,Phase 2,Phase 3,Phase 1 979-32-8
50 Estrogens Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 720)

# Name Status NCT ID Phase Drugs
1 Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission Unknown status NCT01901666 Phase 4 Growth Hormone
2 Status of Growth Hormone/ Insulin-like Growth Factor-1 (GH/IGF-1) Axis and Growth Failure in Ataxia Telangiectasia (AT) Unknown status NCT01052623 Phase 4 Somatropin, Clonidine, L-Arginin-Hydrochloride, Estradiol valerate
3 Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT) Unknown status NCT00915954 Phase 4
4 Effects of Sandostatin LAR® in Acromegaly Unknown status NCT01424241 Phase 4 Sandostatin LAR
5 Effects of Exercise Training on Systemic Inflammation an Muscle Repair According to the Obstructive Chronic Pulmonary Disease (COPD) Phenotype Unknown status NCT01431625 Phase 4
6 Effect of Growth Hormone in Metabolic Syndrome Unknown status NCT00307411 Phase 4 Growth hormone
7 Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant Unknown status NCT00552851 Phase 4 pegvisomant
8 The Effect of a Higher Dose of Dehydroepiandrosterone (DHEA) Supplementation in Poor Responders Unknown status NCT02357472 Phase 4 dehydroepiandrosterone
9 Effect of Omega-3 Supplementation on Serum Level and Gene Expression of IGF-1and IGFBP-3 in Men With CVD. Completed NCT02092584 Phase 4
10 Epidemiology Study on Insulin-like Growth Factor-1 in Children With Idiopathic Short Stature (EPIGROW Study) Completed NCT00710307 Phase 4
11 The Effect of Ophiocephalus Striatus Extract on Levels of IGF-1, Albumin, and MNA Score in Elderly With Malnutrition Completed NCT03065595 Phase 4
12 IGF1 Generation Test Completed NCT00145457 Phase 4
13 A Study to Optimize Growth Hormone Dosing in Children With Chronic Kidney Disease by Measuring IGF-1 Levels in Blood Completed NCT00212758 Phase 4 Nutropin AQ
14 Growth Factor/Insulin-like Growth Factor (GH/IGF)-1 Axis in Obese Subjects in Treatment With Orlistat Completed NCT00991926 Phase 4 Orlistat
15 Study to Compare the Effect of Hormone Replacement Therapy (HRT) on Breast and Cardiovascular Metabolic Markers in Postmenopausal Women Completed NCT00145522 Phase 4 17ß-Estradiol/Dydrogesterone;Tibolone
16 Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects Completed NCT00701363 Phase 4 Lanreotide Autogel 120 mg
17 Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly Completed NCT00376064 Phase 4 Octreotide acetate and cabergoline/Octrotide and Somavert
18 Canadian Pegvisomant Compassionate Study In Acromegalic Patients Completed NCT00151437 Phase 4 Pegvisomant treatment
19 Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients Completed NCT01278342 Phase 4 Sandostatin LAR;pegvisomant;cabergoline
20 Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR Completed NCT00216398 Phase 4 Lanreotide (Autogel formulation)
21 Angiotensin-converting Enzyme (ACE)-Inhibition and Mechanisms of Skeletal Muscle Weakness in Chronic Obstructive Pulmonary Disease (COPD) Completed NCT01014338 Phase 4 Fosinopril
22 Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target Completed NCT01618513 Phase 4 Sandostatin® LAR
23 GH and Cardiovascular Risk Factors Completed NCT01877512 Phase 4 Change in daily dosage of Growth Hormone
24 Predictive Markers in Chinese Growth Hormone Deficiency (GHD) Children Treated With Saizen® Completed NCT01187550 Phase 4 Recombinant human growth hormone (r-hGH)
25 Predictive Markers in GHD and TS Children Treated With SAIZEN® Completed NCT00256126 Phase 4 Saizen
26 A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly Completed NCT00068042 Phase 4 Pegvisomant;Sandostatin LAR
27 Dehydroepiandrosterone (DHEA)Supplementation Pre-IVF(In Vitro Fertilization) Cycles Completed NCT02866253 Phase 4 DHEA
28 Exploratory Clinical Study to Evaluate Sodium Oxybate (Xyrem) on Potential Endocrine Changes Completed NCT00345800 Phase 4 Sodium Oxybate (Xyrem)
29 A Post-Marketing Study of the Immunogenicity of Somatropin (Ribosomal Deoxyribo Nucleic Acid [rDNA] Origin) Injection (Nutropin AQ®) in Children With Growth Hormone Deficiency Completed NCT02311894 Phase 4 Somatropin
30 Biochemical Markers of Growth Response to Growth Hormone Treatment in Children With Idiopathic Short Stature Completed NCT00458263 Phase 4 Somatotropin growth hormone recombinant human
31 An Open-label Phase 4 Study to Explore Immunogenicity of the Liquid Formulation of Saizen® in Subjects With Adult Growth Hormone Deficiency (AGHD) Completed NCT01806298 Phase 4 Saizen® solution for injection (referred as Saizen®)
32 Insulin-like Growth Factor (IGF-I) in Hemodialysis Patients Completed NCT01209403 Phase 4 Glucose-infusion;Glucose-insulin infusion
33 Effect of Somatropin on Left Ventricular Mass in Growth Hormone Deficient Adult Patients Completed NCT01562834 Phase 4 somatropin;placebo
34 Somatuline Autogel: Acromegaly Self/Partner Injection Study Completed NCT00149188 Phase 4 Lanreotide (Autogel formulation)
35 Non Interventional Study For Patients Treated With Somavert® Completed NCT00858143 Phase 4
36 A Study to Evaluate the Risk of Developing a Heart Condition Called Valvular Regurgitation in Patients With Acromegaly Treated With Either Lanreotide or Octreotide Completed NCT00234520 Phase 4
37 A Cross-sectional Study to Investigate the Effect of Topiramate on Bone and Mineral Metabolism in Female Participants With Epilepsy Completed NCT01030094 Phase 4 Topiramate;Carbamazepine;Valproic acid;Normal control
38 Growth Hormone Treatment for the Prevention of Short Stature in Young Girls With Turner Syndrome Before the Age of 4 Years Completed NCT01066052 Phase 4
39 Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues Recruiting NCT02427295 Phase 4 Sandostatin (Octreotide Acetate)
40 Assessment of Changes in Metabolic Activity in Liver & Skeletal Muscle in Patients Suffering From Acromegaly Recruiting NCT02115906 Phase 4
41 Cognitive Dysfunction in MDD Patients Recruiting NCT03187093 Phase 4 Vortioxetine;Escitalopram
42 Pegylated Somatropin (PEG Somatropin) in the Treatment of Children With Growth Hormone Deficiency Recruiting NCT02976675 Phase 4
43 Pegylated Somatropin (PEG Somatropin) in the Treatment of Children With Growth Hormone Deficiency Recruiting NCT03249480 Phase 4
44 Clinical Study of Pegylated Somatropin to Treat Children Growth Hormone Deficiency Recruiting NCT02908958 Phase 4
45 Extension Study of Pegylated Somatropin to Treat Growth Retardation Caused by Endogenous Growth Hormone Deficiency in Children Recruiting NCT03290235 Phase 4 PEG-somatropin
46 Aromatase Inhibitor Growth Study: Letrozole vs. Anastrozole Recruiting NCT02137538 Phase 4 Letrozole;Anastrozole
47 Effects of Oral vs. Non-oral Contraceptives on the GH/IGF-1 Axis Active, not recruiting NCT02367833 Phase 4 Combined Oral Contraceptive;Transdermal Contraceptive;Contraceptive Vaginal Ring
48 Pasireotide LAR and Pegvisomant Study in Acromegaly Active, not recruiting NCT02668172 Phase 4 Pasireotide LAR 60 mg;Pegvisomant
49 Assessing the Impact of Contraceptives on Bone Health Using 41Ca Active, not recruiting NCT02367846 Phase 4 Combined Oral Contraceptive (COC);Contraceptive Vaginal Ring (CVR)
50 The Health Influences of Puberty (HIP) Study Active, not recruiting NCT01775813 Phase 4 Metformin

Search NIH Clinical Center for Insulin-Like Growth Factor I

Genetic Tests for Insulin-Like Growth Factor I

Genetic tests related to Insulin-Like Growth Factor I:

# Genetic test Affiliating Genes
1 Insulin-Like Growth Factor I Deficiency 28 IGF1
2 Insulin-Like Growth Factor 1 Resistance to 28 IGF1R

Anatomical Context for Insulin-Like Growth Factor I

MalaCards organs/tissues related to Insulin-Like Growth Factor I:

38
Breast, Bone, Prostate, Lung, Liver, Pituitary, Heart

Publications for Insulin-Like Growth Factor I

Articles related to Insulin-Like Growth Factor I:

(show top 50) (show all 2639)
# Title Authors Year
1
Targeting Insulin-Like Growth Factor-I and Extracellular Matrix Interactions in Melanoma Progression. ( 29330502 )
2018
2
Influence of ad libitum milk replacer feeding and butyrate supplementation on the systemic and hepatic insulin-like growth factor I and its binding proteins in Holstein calves. ( 29248211 )
2018
3
Correlation of Insulin-Like Growth Factor-I and -II Concentrations at Birth Measured by Mass Spectrometry and Growth from Birth to Two Months. ( 29402777 )
2018
4
Factors correlated with serum insulin-like growth factor-I levels in health check-up subjects. ( 29395967 )
2018
5
Fucoidan downregulates insulin-like growth factor-I receptor levels in HT-29 human colon cancer cells. ( 29328495 )
2018
6
Low serum insulin-like growth factor-I (IGF-I) level is associated with increased risk of vascular dementia. ( 28963885 )
2017
7
Serum insulin-like growth factor-I levels are associated with improved white matter recovery after traumatic brain injury. ( 28574152 )
2017
8
Insulin-like growth factor I enhances the developmental competence of yak embryos by modulating aquaporin 3. ( 28512855 )
2017
9
Growth hormone and insulin-like growth factor-I axis in type 1 diabetes. ( 29249623 )
2017
10
Reference ranges for serum insulin-like growth factor I (IGF-I) in healthy Chinese adults. ( 28976993 )
2017
11
Prediagnostic circulating concentrations of plasma insulin-like growth factor-I and risk of lymphoma in the European Prospective Investigation into Cancer and Nutrition. ( 27870006 )
2017
12
Insulin-like growth factor I and its binding protein-3 are regulators of lactation and maternal responsiveness. ( 28611445 )
2017
13
The role of insulin-like growth factor I-II receptor on development of pleomorphic adenoma. ( 28625007 )
2017
14
Feeling misguided: a comment on the US guidelines on growth hormone and insulin-like growth factor-I treatment in children and adolescents. ( 28604412 )
2017
15
The Role of Growth Hormone and Insulin-Like Growth Factor-I in the Liver. ( 28678199 )
2017
16
Retraction: Targeting 3-Phosphoinoside-Dependent Kinase-1 to Inhibit Insulin-Like Growth Factor-I Induced AKT and p70 S6 Kinase Activation in Breast Cancer Cells. ( 28394928 )
2017
17
Standardization of Growth Hormone and Insulin-like Growth Factor-I Measurements. ( 28516748 )
2017
18
Genetic variants and traits related to insulin-like growth factor-I and insulin resistance and their interaction with lifestyles on postmenopausal colorectal cancer risk. ( 29023587 )
2017
19
A role for astrocytes in cerebellar deficits in frataxin deficiency: Protection by insulin-like growth factor I. ( 28286293 )
2017
20
Pre-diagnosis insulin-like growth factor-I and risk of epithelial invasive ovarian cancer by histological subtypes: A collaborative re-analysis from the Ovarian Cancer Cohort Consortium. ( 28205047 )
2017
21
Growth and Growth hormone - Insulin Like Growth Factor -I (GH-IGF-I) Axis in Chronic Anemias. ( 28467344 )
2017
22
Addition of insulin-like growth factor I to the maturation medium of bovine oocytes subjected to heat shock: effects on the production of reactive oxygen species, mitochondrial activity and oocyte competence. ( 28445838 )
2017
23
Interaction of insulin-like growth factor-I and insulin resistance-related genetic variants with lifestyle factors on postmenopausal breast cancer risk. ( 28478612 )
2017
24
Insulin-like growth factor-I induces chemoresistence to docetaxel by inhibiting miR-143 in human prostate cancer. ( 29291019 )
2017
25
Decreased Serum Insulin-like Growth Factor-I is a Risk Factor for Non-vertebral Fractures in Diabetic Postmenopausal Women. ( 28154269 )
2017
26
A Coordinated Action of Blood-Borne and Brain Insulin-Like Growth Factor I in the Response to Traumatic Brain Injury. ( 28449086 )
2017
27
First-in-man study with a novel PEGylated recombinant human insulin-like growth factor-I. ( 28110155 )
2017
28
To Prime or Not to Prime - Is That Still a Question? A Comment on the US Guidelines on Growth Hormone and Insulin-Like Growth Factor-I Treatment in Children and Adolescents. ( 28505613 )
2017
29
Insulin-like growth factor I reduces the occurrence of necrotizing enterocolitis by reducing inflammatory response and protecting intestinal mucosal barrier in neonatal rats model. ( 29131241 )
2017
30
PEGylated insulin-like growth factor-I affords protection and facilitates recovery of lost functions post-focal ischemia. ( 28325900 )
2017
31
Effect of pre- and postpartum supplementation with lipid-encapsulated conjugated linoleic acid on reproductive performance and the growth hormone-insulin-like growth factor-I axis in multiparous high-producing dairy cows. ( 28456404 )
2017
32
Rejuvenating Effect of Long-Term Insulin-Like Growth Factor-I Gene Therapy in the Hypothalamus of Aged Rats with Dopaminergic Dysfunction. ( 28673122 )
2017
33
Feed restriction and insulin-like growth factor-I (IGF-I) affect the oocyte maturation in matrinxAL Brycon amazonicus. ( 27928979 )
2017
34
Serum reference value of two potential doping candidates-myostatin and insulin-like growth factor-I in the healthy young male. ( 28077934 )
2017
35
Glucocorticoid receptor-mediated insulin-like growth factor-I transcriptional regulation in BeWo trophoblast cells before and after syncytialisation. ( 27500692 )
2016
36
Insulin-Like Growth Factor I Does Not Drive New Bone Formation in Experimental Arthritis. ( 27695067 )
2016
37
Differential roles of the insulin and insulin-like growth factor-I (IGF-I) receptors in response to insulin and IGF-I. ( 27742877 )
2016
38
Lower circulating insulin-like growth factor-I is associated with better cognition in females with exceptional longevity without compromise to muscle mass and function. ( 27744417 )
2016
39
Mycobacterium leprae-induced Insulin-like Growth Factor I attenuates antimicrobial mechanisms, promoting bacterial survival in macrophages. ( 27282338 )
2016
40
Regulation of sex steroid production and mRNAs encoding gonadotropin receptors and steroidogenic proteins by gonadotropins, cyclic AMP and insulin-like growth factor-I in ovarian follicles of rainbow trout (Oncorhynchus mykiss) at two stages of vitellogenesis. ( 27387444 )
2016
41
Defining human insulin-like growth factor I gene regulation. ( 27406741 )
2016
42
Placental weight ratio affects placental mRNA expression of insulin-like growth factor-I and long isoform of the leptin receptor in Plasmodium falciparuminfected pregnant women. ( 28027635 )
2016
43
Low Serum Insulin-Like Growth Factor-I Predicts Cognitive Decline in Alzheimer's Disease. ( 27031487 )
2016
44
Rearing Mozambique tilapia in tidally-changing salinities: Effects on growth and the growth hormone/insulin-like growth factor I axis. ( 27032617 )
2016
45
Clinical Evaluation of Insulin like Growth Factor-I and Vascular Endothelial Growth Factor with Alloplastic Bone Graft Material in the Management of Human Two Wall Intra-Osseous Defects. ( 27790578 )
2016
46
Association of insulin-like growth factor-I with the severity and outcomes of acute ischemic stroke. ( 28435630 )
2016
47
POSTNATAL SERUM INSULIN-LIKE GROWTH FACTOR I AND RETINOPATHY OF PREMATURITY. ( 27529840 )
2016
48
Survivin as a Novel Biomarker in the Pathogenesis of Acne Vulgaris and Its Correlation to Insulin-Like Growth Factor-I. ( 27803511 )
2016
49
Ghrelin, insulin-like growth factor I and adipocytokines concentrations in born small for gestational age prepubertal children after the catch-up growth. ( 27269893 )
2016
50
Insulin-like growth factor-I serum levels and their biological effects on Leishmania isolates from different clinical forms of American tegumentary leishmaniasis. ( 27286813 )
2016

Variations for Insulin-Like Growth Factor I

UniProtKB/Swiss-Prot genetic disease variations for Insulin-Like Growth Factor I:

71
# Symbol AA change Variation ID SNP ID
1 IGF1R p.Arg138Gln VAR_034891 rs121912426
2 IGF1R p.Lys145Asn VAR_034892 rs121912427
3 IGF1R p.Arg739Gln VAR_034895 rs121912429
4 IGF1R p.Asn359Tyr VAR_076247
5 IGF1R p.Tyr865Cys VAR_076248
6 IGF1R p.Arg1256Ser VAR_076249
7 IGF1R p.Arg1337Cys VAR_076250 rs141802822

ClinVar genetic disease variations for Insulin-Like Growth Factor I:

6 (show all 14)
# Gene Variation Type Significance SNP ID Assembly Location
1 IGF1 IGF1, EX4-5DEL deletion Pathogenic
2 IGF1 IGF1, MUTATION IN POLYADENYLATION SIGNAL, T-A single nucleotide variant Pathogenic
3 IGF1 NM_001111284.1(IGF1): c.226G> A (p.Val76Met) single nucleotide variant Pathogenic rs121912430 GRCh37 Chromosome 12, 102813415: 102813415
4 IGF1R NM_000875.4(IGF1R): c.413G> A (p.Arg138Gln) single nucleotide variant protective rs121912426 GRCh37 Chromosome 15, 99251109: 99251109
5 IGF1R NM_000875.4(IGF1R): c.435A> C (p.Lys145Asn) single nucleotide variant protective rs121912427 GRCh37 Chromosome 15, 99251131: 99251131
6 IGF1R NM_000875.4(IGF1R): c.265C> T (p.Arg89Ter) single nucleotide variant protective rs121912428 GRCh37 Chromosome 15, 99250961: 99250961
7 IGF1R NM_000875.4(IGF1R): c.2216G> A (p.Arg739Gln) single nucleotide variant protective rs121912429 GRCh37 Chromosome 15, 99465391: 99465391
8 IGF1R NM_000875.4(IGF1R): c.1532G> A (p.Arg511Gln) single nucleotide variant protective rs33958176 GRCh37 Chromosome 15, 99454613: 99454613
9 IGF1 NM_001111283.2(IGF1): c.292C> T (p.Arg98Trp) single nucleotide variant Pathogenic rs587779350 GRCh37 Chromosome 12, 102813397: 102813397
10 IGF1R NM_001291858.1(IGF1R): c.3184-2A> T single nucleotide variant Likely pathogenic rs886042346 GRCh37 Chromosome 15, 99478543: 99478543
11 IGF1R NM_001291858.1(IGF1R): c.361G> A (p.Glu121Lys) single nucleotide variant protective GRCh37 Chromosome 15, 99251057: 99251057
12 IGF1R NM_001291858.1(IGF1R): c.700G> A (p.Glu234Lys) single nucleotide variant protective GRCh38 Chromosome 15, 98891384: 98891384
13 IGF1R NM_000875.4(IGF1R): c.119G> T (p.Arg40Leu) single nucleotide variant protective GRCh38 Chromosome 15, 98707586: 98707586
14 IGF1R NM_001291858.1(IGF1R): c.2201G> T (p.Arg734Ile) single nucleotide variant protective GRCh38 Chromosome 15, 98916876: 98916876

Expression for Insulin-Like Growth Factor I

Search GEO for disease gene expression data for Insulin-Like Growth Factor I.

Pathways for Insulin-Like Growth Factor I

Pathways related to Insulin-Like Growth Factor I according to KEGG:

36
# Name Kegg Source Accession
1 PI3K-Akt signaling pathway hsa04151
2 Oocyte meiosis hsa04114
3 Focal adhesion hsa04510
4 Adherens junction hsa04520
5 Long-term depression hsa04730
6 Progesterone-mediated oocyte maturation hsa04914

Pathways related to Insulin-Like Growth Factor I according to GeneCards Suite gene sharing:

(show top 50) (show all 112)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.97 AKT1 AKT2 EGF GH1 IGF1 IGF1R
2
Show member pathways
13.92 AKT1 AKT2 EGF GH1 IGF1 IGF1R
3
Show member pathways
13.89 GH1 IGF1 IGF2 IGFBP1 IGFBP2 IGFBP3
4
Show member pathways
13.82 AKT1 AKT2 EGF GH1 IGF1 IGF1R
5
Show member pathways
13.64 AKT1 AKT2 EGF GH1 IGF1 IGF1R
6
Show member pathways
13.56 AKT1 AKT2 EGF GH1 GHR IGF1
7
Show member pathways
13.47 AKT1 AKT2 EGF GH1 IGF1 IGF1R
8
Show member pathways
13.42 AKT1 AKT2 EGF IGF1 IGF2 ITGA6
9
Show member pathways
13.41 AKT1 EGF GH1 IGF1 IGF1R IGF2
10
Show member pathways
13.38 AKT1 AKT2 EGF GH1 IGF1 IGF1R
11
Show member pathways
13.36 AKT1 EGF GH1 IGF1 IGF1R IGF2
12
Show member pathways
13.33 AKT1 AKT2 EGF GH1 GHR IGF1
13
Show member pathways
13.19 AKT1 AKT2 EGF INS INSR IRS1
14
Show member pathways
13.18 AKT1 EGF GH1 IGF1 IGF1R IGF2
15
Show member pathways
13.16 AKT1 AKT2 EGF IGF1 IGF1R INS
16
Show member pathways
13.15 AKT1 AKT2 EGF GH1 IGF1 IGF1R
17
Show member pathways
13.1 IGF1 IGF1R IGF2 INSR ITGA6 ITGAV
18
Show member pathways
13.03 AKT1 AKT2 EGF IGF1 IGF1R ITGA6
19 12.97 AKT1 AKT2 EGF IGF1 IGF1R IGF2
20
Show member pathways
12.93 AKT1 INS INSR IRS1 ITGA6 ITGAV
21
Show member pathways
12.91 AKT1 AKT2 IGF1 IGF1R IGF2 IRS1
22 12.89 AKT1 AKT2 EGF IGF1 IGF1R IGF2
23
Show member pathways
12.88 AKT1 AKT2 IGF1 IGF1R IGF2
24
Show member pathways
12.88 AKT1 AKT2 EGF IGF1 IGF1R IGF2
25
Show member pathways
12.85 AKT1 AKT2 INS INSR IRS1
26
Show member pathways
12.84 AKT1 AKT2 EGF INS INSR IRS1
27
Show member pathways
12.83 AKT1 AKT2 EGF GH1 GHR IGF1
28
Show member pathways
12.82 AKT1 AKT2 EGF IGF1 IGF1R IGF2
29
Show member pathways
12.82 AKT1 AKT2 EGF GH1 GHR IGF1
30
Show member pathways
12.81 AKT1 AKT2 INS INSR IRS1
31
Show member pathways
12.79 AKT1 EGF GH1 IGF1 IGF2
32 12.72 EGF INS ITGA6 ITGAV ITGB3
33
Show member pathways
12.7 AKT1 AKT2 EGF IGF1 IGF1R IRS1
34
Show member pathways
12.66 IGFBP1 IGFBP2 IGFBP3 IGFBP4 IGFBP5 IGFBP6
35
Show member pathways
12.65 AKT1 AKT2 IGF1R INS INSR IRS1
36
Show member pathways
12.64 AKT1 AKT2 IGF1 IGF1R INS INSR
37
Show member pathways
12.6 AKT1 AKT2 GH1 INS IRS1
38
Show member pathways
12.58 AKT1 AKT2 IGF1 IGF1R INS INSR
39
Show member pathways
12.56 AKT1 AKT2 IGF1R INSR ITGAV
40 12.54 AKT1 AKT2 IGF1R IGFBP1 IGFBP2 IGFBP3
41
Show member pathways
12.52 AKT1 AKT2 EGF INS INSR
42
Show member pathways
12.49 EGF ITGA6 ITGAV ITGB3
43
Show member pathways
12.49 AKT1 AKT2 EGF GH1 GHR
44
Show member pathways
12.47 AKT1 AKT2 ITGAV ITGB3
45
Show member pathways
12.46 AKT1 AKT2 IGF1 IGF1R INS
46
Show member pathways
12.46 AKT1 AKT2 EGF IGF1 IGF1R INSR
47
Show member pathways
12.43 AKT1 IRS1 ITGA6 ITGAV
48 12.42 AKT1 AKT2 IGF1 IGF1R IGF2 ITGAV
49
Show member pathways
12.39 AKT1 AKT2 IGF1 IGF1R IRS1
50
Show member pathways
12.37 AKT1 AKT2 IGF1R INSR ITGA6 ITGAV

GO Terms for Insulin-Like Growth Factor I

Cellular components related to Insulin-Like Growth Factor I according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum lumen GO:0005788 9.92 IGFBP1 IGFBP3 IGFBP4 IGFBP5 INS
2 receptor complex GO:0043235 9.77 EGF GHR IGF1R INSR ITGB3
3 ruffle membrane GO:0032587 9.72 AKT2 ITGAV ITGB3
4 platelet alpha granule lumen GO:0031093 9.71 EGF IGF1 IGF2
5 integrin complex GO:0008305 9.63 ITGA6 ITGAV ITGB3
6 insulin receptor complex GO:0005899 9.51 INSR IRS1
7 alphav-beta3 integrin-HMGB1 complex GO:0035868 9.49 ITGAV ITGB3
8 alphav-beta3 integrin-PKCalpha complex GO:0035866 9.48 ITGAV ITGB3
9 growth hormone receptor complex GO:0070195 9.43 GH1 GHR
10 integrin alphav-beta3 complex GO:0034683 9.4 ITGAV ITGB3
11 insulin-like growth factor ternary complex GO:0042567 9.33 IGF1 IGFBP3 IGFBP5
12 insulin-like growth factor binding protein complex GO:0016942 9.13 IGF1 IGFBP3 IGFBP5
13 alphav-beta3 integrin-IGF-1-IGF1R complex GO:0035867 8.92 IGF1 IGF1R ITGAV ITGB3
14 extracellular region GO:0005576 10.1 EGF GH1 GHR IGF1 IGF2 IGFBP1
15 extracellular space GO:0005615 10 EGF GH1 GHR IGF1 IGF2 IGFBP1

Biological processes related to Insulin-Like Growth Factor I according to GeneCards Suite gene sharing:

(show top 50) (show all 66)
# Name GO ID Score Top Affiliating Genes
1 platelet degranulation GO:0002576 9.98 EGF IGF1 IGF2 ITGB3
2 glucose homeostasis GO:0042593 9.98 AKT1 IGFBP5 INS INSR IRS1
3 activation of MAPK activity GO:0000187 9.97 EGF GHR IGF1 INSR
4 cellular response to insulin stimulus GO:0032869 9.96 AKT1 AKT2 GHR INSR IRS1
5 regulation of cell growth GO:0001558 9.95 IGFBP2 IGFBP3 IGFBP4 IGFBP5 IGFBP6
6 regulation of growth GO:0040008 9.93 IGFBP2 IGFBP3 IGFBP4 IGFBP5
7 glucose metabolic process GO:0006006 9.92 AKT1 AKT2 IGF2 IGFBP5 INS
8 positive regulation of cell growth GO:0030307 9.91 AKT1 IGFBP1 INS
9 positive regulation of mitotic nuclear division GO:0045840 9.91 EGF IGF1 IGF2 INS INSR
10 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.91 EGF GH1 GHR IGF1 IGF2 INS
11 cellular protein metabolic process GO:0044267 9.91 IGF1 IGF2 IGFBP1 IGFBP2 IGFBP3 IGFBP4
12 regulation of cell migration GO:0030334 9.9 AKT1 AKT2 ITGB3
13 cellular response to organic cyclic compound GO:0071407 9.9 AKT1 IGFBP5 ITGA6
14 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.89 GH1 IGF1 INS
15 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.89 GH1 GHR IGF1
16 positive regulation of DNA replication GO:0045740 9.89 IGF1 IGF1R INS INSR
17 activation of protein kinase B activity GO:0032148 9.88 AKT1 IGF1 INS INSR
18 positive regulation of nitric oxide biosynthetic process GO:0045429 9.87 AKT1 INS INSR
19 phosphatidylinositol-mediated signaling GO:0048015 9.87 IGF1 IGF1R IRS1
20 phosphatidylinositol 3-kinase signaling GO:0014065 9.87 AKT1 IGF1 IGF1R IRS1
21 negative regulation of extrinsic apoptotic signaling pathway GO:2001237 9.86 IGF1 ITGA6 ITGAV
22 ERK1 and ERK2 cascade GO:0070371 9.85 EGF IGF1 ITGAV
23 glucose transport GO:0015758 9.84 AKT1 GH1 INS
24 positive regulation of activated T cell proliferation GO:0042104 9.84 IGF1 IGF2 IGFBP2
25 regulation of glucose metabolic process GO:0010906 9.83 IGFBP3 IGFBP4 IGFBP5
26 insulin-like growth factor receptor signaling pathway GO:0048009 9.83 AKT1 GHR IGF1 IGF1R IRS1
27 positive regulation of glycolytic process GO:0045821 9.82 IGF1 INS INSR
28 cell-substrate adhesion GO:0031589 9.82 ITGA6 ITGAV ITGB3
29 cell adhesion mediated by integrin GO:0033627 9.81 ITGA6 ITGAV ITGB3
30 response to growth hormone GO:0060416 9.8 AKT1 GHR IGFBP5
31 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.8 GH1 IGF1 IGFBP3 IGFBP4 IGFBP5
32 positive regulation of glucose import GO:0046326 9.8 AKT1 AKT2 IGF1 INS INSR IRS1
33 positive regulation of insulin receptor signaling pathway GO:0046628 9.79 IGF2 INS IRS1
34 positive regulation of glucose metabolic process GO:0010907 9.78 AKT1 AKT2 IRS1
35 type B pancreatic cell proliferation GO:0044342 9.77 IGFBP3 IGFBP4 IGFBP5
36 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.74 ITGAV ITGB3
37 striated muscle cell differentiation GO:0051146 9.74 AKT1 IGFBP5
38 positive regulation of lipid biosynthetic process GO:0046889 9.73 AKT1 INS
39 amyloid-beta clearance GO:0097242 9.73 IGF1R INSR
40 dendritic spine maintenance GO:0097062 9.73 IGF1R INSR
41 positive regulation of fatty acid beta-oxidation GO:0032000 9.72 AKT2 IRS1
42 negative regulation of lipid storage GO:0010888 9.72 ITGAV ITGB3
43 positive regulation of mitochondrial membrane potential GO:0010918 9.72 AKT1 AKT2
44 growth hormone receptor signaling pathway GO:0060396 9.71 GH1 GHR
45 cell-substrate junction assembly GO:0007044 9.71 ITGA6 ITGB3
46 peripheral nervous system myelin maintenance GO:0032287 9.71 AKT1 AKT2
47 positive regulation of respiratory burst GO:0060267 9.71 INS INSR
48 neuron projection maintenance GO:1990535 9.71 INS INSR
49 apolipoprotein A-I-mediated signaling pathway GO:0038027 9.7 ITGAV ITGB3
50 positive regulation of protein complex disassembly GO:0043243 9.7 IGF1R INSR

Molecular functions related to Insulin-Like Growth Factor I according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 receptor binding GO:0005102 9.97 IGFBP1 IGFBP2 IGFBP4 IGFBP6 ITGAV
2 growth factor activity GO:0008083 9.86 EGF GH1 IGF1 IGF2
3 integrin binding GO:0005178 9.81 IGF1 ITGA6 ITGAV ITGB3
4 hormone activity GO:0005179 9.8 GH1 IGF1 IGF2 INS
5 insulin receptor binding GO:0005158 9.77 IGF1 IGF1R IGF2 INS IRS1
6 growth factor binding GO:0019838 9.73 IGFBP1 IGFBP2 IGFBP3 IGFBP4 IGFBP5 IGFBP6
7 protein kinase C binding GO:0005080 9.72 AKT1 IRS1 ITGAV
8 insulin-like growth factor receptor binding GO:0005159 9.72 IGF1 IGF2 INS INSR IRS1
9 fibronectin binding GO:0001968 9.71 IGFBP3 IGFBP5 ITGAV ITGB3
10 insulin-like growth factor binding GO:0005520 9.7 IGF1R IGFBP1 IGFBP2 IGFBP3 IGFBP4 IGFBP5
11 insulin-like growth factor I binding GO:0031994 9.7 IGF1R IGFBP1 IGFBP2 IGFBP3 IGFBP4 IGFBP5
12 phosphatidylinositol 3-kinase binding GO:0043548 9.65 IGF1R INSR IRS1
13 neuregulin binding GO:0038132 9.61 ITGA6 ITGAV ITGB3
14 insulin receptor substrate binding GO:0043560 9.58 IGF1R INSR
15 insulin binding GO:0043559 9.54 IGF1R INSR
16 C-X3-C chemokine binding GO:0019960 9.52 ITGAV ITGB3
17 insulin-like growth factor II binding GO:0031995 9.17 IGFBP1 IGFBP2 IGFBP3 IGFBP4 IGFBP5 IGFBP6
18 protein binding GO:0005515 10.43 AKT1 AKT2 EGF GH1 GHR IGF1

Sources for Insulin-Like Growth Factor I

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....